Omega Diagnostics’ FY2016 results were in line with our expectations. Sales rose 5% (7% CER), driven by Food Intolerance (+19%) which offset expected declines in Allergy and Autoimmune and a flat Infectious Disease performance. We expect Allersys to launch in FY 2017. Moreover, there is a clearer roadmap to market for Visitect CD4, for which some of its technical challenges have seemingly been resolved. This enables management to invest more confidently for growth, which is reflect
